Lynch Samuel Eugene 4
4 · BIOMIMETIC THERAPEUTICS, INC. · Filed Mar 5, 2013
Insider Transaction Report
Form 4
Lynch Samuel Eugene
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2013-03-01$3.47/sh+51,000$176,970→ 1,300,546 total - Exercise/Conversion
Common Stock
2013-03-01$2.08/sh+170,000$353,600→ 1,470,546 total - Disposition to Issuer
Common Stock
2013-03-01−1,392,923→ 0 total - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−80,000→ 0 totalExercise: $12.59Exp: 2017-01-16→ Common Stock (80,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−85,000→ 0 totalExercise: $13.45Exp: 2021-01-19→ Common Stock (85,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−75,000→ 0 totalExercise: $11.97Exp: 2020-02-03→ Common Stock (75,000 underlying) - Tax Payment
Common Stock
2013-03-01$9.07/sh−77,623$704,336→ 1,392,923 total - Exercise/Conversion
Stock Options (right to buy)
2013-03-01−51,000→ 0 totalExercise: $3.47Exp: 2014-12-01→ Common Stock (51,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−45,000→ 0 totalExercise: $14.41Exp: 2018-02-07→ Common Stock (45,000 underlying) - Disposition to Issuer
Common Stock
2013-03-01−5,550→ 0 total(indirect: By Spouse) - Exercise/Conversion
Stock Options (right to buy)
2013-03-01−170,000→ 0 totalExercise: $2.08Exp: 2022-02-28→ Common Stock (170,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−205,703→ 0 totalExercise: $13.88Exp: 2018-02-27→ Common Stock (205,703 underlying) - Disposition to Issuer
Stock Options (right to buy)
2013-03-01−80,000→ 0 totalExercise: $8.54Exp: 2019-02-26→ Common Stock (80,000 underlying)
Footnotes (9)
- [F1]Includes shares acquired by the Reporting Person since the previous Form 4 filing (on 3/30/2012), consisting of 8,774 shares purchased through the Issuer's Employee Stock Purchase Plan and 1,381 shares awarded to his 401(k) Profit Sharing Plan account via the 2012 Company match.
- [F2]This transaction represents a withholding of shares to cover the payment of exercise price and federal tax liability pursuant to an exercise of non-qualified stock options.
- [F3]Disposed of pursuant to the Agreement and Plan of Merger ("Merger Agreement") dated as of November 19, 2012, by and among the Company, Wright Medical Group, Inc. ("Wright"), Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC in exchange for the following merger consideration per share of the Company's common stock: (a) $1.50 in cash, without interest; (b) 0.2482 of a share of Wright's common stock; and (c) one contingent value right ("CVR") issued by Wright.
- [F4]Dr. Samuel E. Lynch disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them.
- [F5]Option exercised. Pursuant to the Merger Agreement, this stock option was conditionally vested to 100% subject to exercise upon the merger transaction. The reporting person received merger consideration described in footnote (3) above.
- [F6]Option canceled. Pursuant to the Merger Agreement, the reporting person entered into an agreement with the issuer to terminate stock options with an exercise price greater than $13.00.
- [F7]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 41,745 shares of Wright common stock at an exercise price of $24.13 per share.
- [F8]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 41,745 shares of Wright common stock at an exercise price of $16.37 per share.
- [F9]Pursuant to the Merger Agreement, the stock options granted by the issuer converted into options to purchase 39,136 shares of Wright common stock at an exercise price of $22.94 per share.